Horizon Investment Services LLC Has $1.24 Million Holdings in Phibro Animal Health Corporation $PAHC

Horizon Investment Services LLC boosted its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 241.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,241 shares of the company’s stock after acquiring an additional 23,501 shares during the quarter. Horizon Investment Services LLC owned 0.08% of Phibro Animal Health worth $1,242,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. boosted its position in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares during the last quarter. Hughes Financial Services LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter valued at about $40,000. Rothschild Investment LLC lifted its holdings in shares of Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after buying an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health during the 3rd quarter valued at about $61,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised its earnings estimates for Phibro Animal Health across several periods, including FY2026 to $3.05 EPS, FY2027 to $3.18 EPS, and FY2028 to $3.35 EPS, signaling a more constructive view of the company’s earnings power.
• Positive Sentiment: Near-term estimates were also nudged higher, including Q4 2026 to $0.69 EPS, Q1 2027 to $0.79 EPS, Q2 2027 to $0.85 EPS, Q3 2027 to $0.76 EPS, and Q1 2028/Q3 2028 to $0.82 EPS each, which may support investor confidence in execution.
• Neutral Sentiment: Zacks Research kept a Hold rating on PAHC, so the revisions are supportive but not a strong bullish upgrade.
• Neutral Sentiment: The stock still trades well below its 50-day and 200-day moving averages, so the shares remain in a weaker technical position despite the analyst optimism.

Phibro Animal Health Stock Up 0.9%

Shares of PAHC stock opened at $31.53 on Friday. The stock’s 50 day simple moving average is $43.88 and its 200 day simple moving average is $44.77. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. Phibro Animal Health Corporation has a twelve month low of $23.57 and a twelve month high of $60.08. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 0.48 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts predict that Phibro Animal Health Corporation will post 3.08 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 10,560 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $52.68, for a total value of $556,300.80. Following the transaction, the chief executive officer directly owned 80,360 shares of the company’s stock, valued at approximately $4,233,364.80. This trade represents a 11.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 69,648 shares of company stock valued at $3,759,028. 50.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

PAHC has been the subject of several research reports. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup reduced their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Finally, Weiss Ratings lowered Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.